This study is a phase 3 study that will be comparing recurrence-free survival (RFS) between patients withlocally advanced renal cell carcinoma randomly assigned toperioperative nivolumab in conjunction with radical or partialnephrectomy with patients randomized to surgery alone.

You are being asked to take part in this research study because you have cancer in your kidney, which is planned to be removed by a surgeon. The standard treatment for your disease is to remove the kidney or part of the kidney that contains the cancer by surgery. You are then monitored after surgery with imaging scans and exams to watch for any possiblesigns of recurrence (close observation)

The purpose of this voluntary research study is to see if neratinib, endocrine therapy, and trastuzumab completely shrink breast tumors before having breast cancer surgery. You will need to have the following exams, tests, or procedures: blood draws, ECG, Echo or MUGA, ultrasound, MRI, receive study treatment, and breast biopsy.

Participants will be required to receive study treatments, laboratory assessments, undergo breast biopsy, and radiologic assessments,

This study, part of a broader dissertation on terrorism and radicalization, aims to experimentally determine how collective punishment fuses individual identities to that of an ingroup, expanding extant knowledge of identity fusion theory.

The purpose of this study is to evaluate the investigational drug AMXT-1501 (a pill taken by mouth) in combination with the study drug difluoromethylornithine (DFMO) for infusion administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). An investigational drug is one that has not been approved by the U.S. Food & Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat.

You will undergo a number of standard tests and research-related procedures before being able to enroll on this study.

Participants 18 years and older who meet the diagnostic criteria for the basal cell nevus (Gorlin) syndrome will be assigned to receive either Patidegib Gel 2% or Placebo (no active medicine) to apply twice daily for 12 months. The assignment will be made according to sex assigned at birth, age, and number of BCC lesions at the treatment area at Baseline. The primary endpoint is a comparison between the 2 treatment arms of the number of new BCCs at Month 12 compared to Baseline. The BCCs will be imaged and tracked consistently throughout the study to identify new BCCs and to confirm their diagnosis by dermoscopy (handheld instrument with a 15x magnification lens and a cross-polarized light source).

Participants will participate in 15 visits over approximately 14 months (attend 6 in person visits along with 9 phone call visits). In addition, participants will receive study medication to apply twice a day for 12 months and undergo clinical tests at various time points, which include blood tests, ECG, complete questionnaires/diary, skin exam and skin photographs.

Compensation is provided for eligible participants.

This research aims to learn more about your daily thoughts, behaviors, and their impact on social relationships. We want to understand the different qualities of day-to-day thoughts, how these might affect your mood, and how this may influence how you behave in social interactions. We will first ask you to complete a set of structured questionnaires and a brief 30-minute psychological interview via Zoom. This will be followed by a training session in which you will learn how to use your smartphone to track your social interactions and related daily thoughts and behaviors eight times a day for eight days.

You will undergo an initial assessment visit conducted on Zoom, where you will provide informed consent and undergo screening through a brief 30-minute clinical interview. Based on your responses, we will know if you can participate in the study. If eligible, you will be invited to the second part of the study. If so, during the same session, you will then receive a brief half-hour training session reviewing instructions on using a mobile application to complete daily surveys and then complete a series of online questionnaires.When you leave this session, for the next eight days, you will complete eight (approximately 2-minute) questionnaires daily between 10 a.m. and 10 p.m. On the third day, you will attend a compliance check via Zoom to review your progress in the present study.

$20

The study goal is to develop robots that can learn simple games by interviewing humans. The robot interview strategies are represented as Markov Decision Process policies, and are developed offline through robot interactions with simulated interviewees. The investigator can set the simulated interviewee to respond to the robot's queries with different amounts of information. The games include board games like Connect 4, Quarto, and Checkers. The communication between the robot and simulated interviewee is in a formal language like first order logic. After a simulated dialogue, the robot will have more or less knowledge of the game, depending on the conditions of the simulated interviewee. Human subjects will interact with the robots in two ways. First, to test the utility of the new knowledge, human subjects will participate in experiments where they play the game with virtual robots that have learned the game under different conditions. Second, to investigate the kinds of misunderstandings of questions and answers that might arise if the robot could interview a human, we will present subjects with extracts from the formal language dialogues that we have mapped to English in different ways, and ask subjects to imagine how they would express the same meaning in English, or answer questions in different ways, or what sorts of misunderstandings they might imagine in a real dialogue.

This is a drug study that will evaluate how well the investigational drug works compared to a placebo following CAR-T cell therapy. Participants will be required to keep all your scheduled visits, receive drug treatment, blood draws, imaging, and possibly a tumor biopsy.

Participants will be required to receive the study treatments including CAR-T infusion, blook tests, imaging, tumor biopsy, and study medications.

A randomized placebo-controlled study to evaluate the efficacy and safety of VIB4920 in study participants with active lupus nephritis

Patients come for in-person visits at the Penn State Hershey main hospital location. There will be blood draws, physical exams, and questionnaires spread out across 60 weeks.

In contexts where people speak different dialects of the same language, how much overlap is there between the dialects, and what are the genuine grammatical differences? This study explores this question through a series of three experiments examining how people from three different dialects understand a variety of negative sentences (e.g., I didn't eat nothing). The results will contribute to our understanding of linguistic diversity.

Participants will sit at a computer and have their eye movements tracked by a camera as they read or listen to sentences and look at pictures on the screen.

$15 per hour

This study investigates whether persons with aphasia understand and process sentences with vernacular features in a manner similar to more typical populations. Participants will rate sentences on their naturalness and on whether they make sense, and they will also read sentences while we track their eye movements.

In an increasingly global environment, both within the US and abroad, the ability to rapidly gain native-like linguistic competence is a critical asset. The ability to use an L2 in a way that is both expected and recognized by its native speakers is important both to the broad public, and to specific sectors, such as military personnel, that must develop native-like competence in a foreign language in a limited amount of time. The studies conducted under this IRB protocol will examine how learners/speakers of a second language acquire and process multi-word units (e.g., carry a business; run a store) in their second language, and how knowledge from the first language might influence the learning and processing of multi-word units in a second language.

Participants will complete a number of simple tasks on a computer in English and/or in Spanish (depending on language background).

$12/hour (behavioral sessions); $18/hour (EEG sessions); $20 bonus at completion of study when at least 3 behavioral sessions or 2 EEG sessions are required.

This study seeks to verify the findings of the CHARM I pilot study by conducting a multi-center clinical trial. We hypothesize that:•Pancreatic cyst infusion with a specifically designed drug therapy cocktail following normal saline lavage will result in cyst destruction rates that do not significantly differ from those achieved by alcohol-based cyst treatment (ethanol lavage followed by infusion of the same chemotherapeutic cocktail).•The removal of alcohol from the procedure will decrease both serious and minor adverse event rates associated with pancreatic cyst treatment.•There may be molecular markers contained within the fluid of these cystic tumors which identify cysts that are favorable to or resistant to EUS-guided fine needle infusion using this drug combination. As such, we will test all treated cysts for 10 of the best known molecular markers for evaluation in post study analysis. We expect that administering a specifically designed chemotherapeutic cocktail without prior alcohol lavage will result in an equivalent rate of cyst resolution with fewer complications when compared to alcohol. The results of this study will provide important information about the most efficient and safest method for treating premalignant pancreatic cysts, an important step for treating these lesions with a minimally invasive technique and preventing their progression to cancer. Standard alternative treatment options for this patient group (if not taking part in this study) would be ongoing periodic radiographic monitoring with MR or CT imaging waiting for signs of cancer to develop or to consider surgical removal of the affected tissue.

Patients will have to sign the consent form to participate in the trial

This research is an attempt to understand the components of empathy and the cultural factors that shape its development. I am seeking about 200 Master's-level counseling students in the U.S. to complete the online survey. The survey takes about 15 minutes to complete, and participants will have chances to win Amazon gift cards and to learn the study results.

A brain-computer interface (BCI) is a device that has the potential to restore communication by translating voluntarily controlled brain signals of intent. The P300 speller, a popular BCI paradigm, relies on the generation of a P300 evoked potential when a user is presented a rare and unpredictable target stimulus amidst a larger pool of non-target stimuli. This evoked potential is used to control a spelling interface. Those with advanced ALS experiencing the loss of voluntary muscular control may also experience cognitive changes that result in decreased capacity for BCI control using the P300 speller.With this pilot study, we aim to validate the performance of a combination of eye tracking and standard sensory testing to quantify intact sensory and cognitive processes necessary for the generation of a P300 response. Additionally, we will evaluate the association of these correlates with performance on a multisensor P300 spelling task, where brain potentials are evoked using a combination of visual, auditory, and tactile stimuli. The goal is to demonstrate the viability of this system for future use in a patient group.

A brain-computer interface (BCI) is a device that has the potential to restore communication by direct translation of brain signals into computer commands. The BCI used in this study, the P300 Speller, relies on the generation of a P300 evoked potential when a user is presented a rare and unpredictable target stimulus amidst a larger pool of non-target stimuli. During this 2-hour, single session study, we aim to use a combination of eye tracking and sensory testing to quantify sensory and cognitive processes necessary for the generation of a P300 response. We will test the performance of a multisensory P300 spelling task, where brain potentials are evoked using a combination of visual, auditory, and tactile stimuli.

We are asking you to take part in this voluntary research study because you have a brain tumor (glioblastoma) that has gotten worse despite first treatment.The purpose of this voluntary research study is to is to learn if the SonoCloud-9 (SC9) implantable device can be used in combination with Carboplatin chemotherapy to help control glioblastoma at recurrence. Neither Sonocloud-9 (SC9) in combination with Carboplatin chemotherapy is not FDA approved.

As part of your routine care, you will be asked to undergo surgery to remove the tumor that has come back. You will be randomized into one of the treatment groups. If you are in the study drug group the surgeon will insert the SonoCloud-9 device (SC9) implant into the skull bone at the end of the tumor resection surgery. If you are in the routine treatment group, the surgeon will close the wound without implanting the SC9 device.The treatment itself will start within 12 to 21 days after the randomization.-If you are in the study drug group you will receive up to 7 doses (every 3 weeks) of Carboplatin at the same time the SonoCloud-9 device is being activated. Further details on the procedures are described below. A brain MRI (Magnetic Resonance Imaging) scan will be performed after the first cycle as part of the research to evaluate opening of the BBB (blood-brain barrier). -If you are in the routine treatment group, you will receive up to 4 doses of Lomustine (every 6 weeks), or, if considered as best appropriate, up to 6 doses of Temozolomide (every 4 weeks). Additional in-person hospital visits or telehealth consultations by video or phone will be performed at regular intervals.

$350.00

18 month trial of elagolix and combined oral contraceptives for women with moderate to severe endometriosis related pain

Subjects will have a screening period of approximately 45 days. If eligible, there will be a 3 month double blind placebo controlled treatment period followed by an open label period of 15 months where all subjects will receive the study medication. Total treatment period is 18 months followed by a one month follow up.Onsite visits are once a month during screening and up until Month 3 when onsite visits will be every 3 months through Month 18.Tests include blood draws at each onsite visit, one ultrasound, an EKG, and 4 DXA scans.

$1475.00

Description: This research study is to assess energetic status, reproductive health, and bone health in a population of young exercising men. Secondarily, this study will also explore how diet, fitness, cardiovascular function, eating behaviors, stress, cognitive function, and sleep related to energy and reproductive outcomes in exercising men. Eligible young men (age 18-35) are those who are generally healthy and either a) exercising or b) not exercising.

There will be essentially 5 study visits - The first visit will include informed consent to take part in the study & completion of questionnaires and measurement of anthropometrics. Visit 2 will include tests of your metabolism, a blood draw, a saliva collection, and assessment of diet and physical activity. Visit 3 will be a short visit for a saliva collection. Visit 4 will include tests of stress (a hair sample), body composition, bone health, aerobic and anaerobic fitness, cognitive testing, and reproductive function. Visit 5 will consist of a results meeting and return of wearable devices and logs.

The purpose of this study is to compare the usual treatment alone to using the study drug niraparib plus the usual treatment. The addition of niraparib to the usual treatment could prevent your cancer from growing or returning. But, it could also cause side effects, which are described in the risks section below. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To be better, the study approach should increase the chance of remaining cancer free to 50 out of 100 participants after 2 years, or a 20% improvement compared to the usual approach.

This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To be better, the study approach should increase the chance of remaining cancer free to 50 out of 100 participants after 2 years, or a 20% improvement compared to the usual approach.

The purpose of this research study is to better understand how leg blood flow is regulated in healthy people and patients with Peripheral Arterial Disease (PAD). It is also being done to examine if a standard-of-care peripheral intervention procedure to improve blood flow to the leg in PAD patients will improve the oxygen delivery and blood flow response to exercise in their legs.

Healthy subjects will participate in 1 visit and perform handgrip and foot (plantar flexion) exercises while several non-invasive measurements are recorded.

You will receive $25 per hour for your participation in this research study

This trial will examine different doses of JANX007 to find the safest dose to treat metastatic castration resistant prostate cancer (mCRPC)

Participants will be required to come to all clinic visits, report any symptoms they are having and all medications they are taking, including over the counter medications.

The purpose of the study is to test how social decisions are affected by possible risk of infection. We aim to examine how choices in a risky social decision-making situation can influenced by viewing images of infection threat (e.g., person with runny nose) vs. images of neutral scenes or other threatening scenes.

There will be one 90-minute in-person visit. Participants will be asked to have electrodes placed on their skin to record their physiological signals, answer questionnaires, and complete a decision-making task on the computer while looking at different images.

$30

The purpose of this study is to examine how individual differences in interoception (the ability to sense, interpret, and act on bodily feelings like hunger, fullness, thirst, hot, cold, etc.) relate to eating behaviors in children ages 7-10 years. Findings will inform whether interventions targeting interoceptive awareness may be helpful for prevention of obesity and related chronic diseases.

Child and parent will attend 2 visits at the Clinical Research Center, about 1-3 weeks apart.At visit 1 (~3 hours)- Your child's height and weight will be measured- Your child's percent body fat will be measured using an x-ray based technology- Your child will wear a heart rate monitor and will complete tasks where they are asked to notice or count their heartbeat- Your child will complete questionnaires via an interview with a researcher- Your child will be asked to drink several glasses of water to measure their stomach sensations- You will complete questionnairesAt visit 2 (~2.5 hours)- We will collect 4 saliva samples from your child- Your child will eat a meal and taste snacks- Your child will play brain games on an iPad- You will complete questionnaires

$100

This study will allow us to explore the influence of the COVID-19 pandemic as well as sociodemographic factors on undergraduate and graduate medical students’ mental health measured by stress, anxiety, and resilience, and to study their online learning experience during the pandemic.

Participants in the PIVOT-006 study will either receive surgical treatment plus cretostimogene or surgical treatment alone.This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by CG0070 vs TURBT for the treatment of patients with IR-NMIBC.The purpose of this study is to see if cretostimogene can reduce the risk of your bladder cancer returning, or coming back as quickly as if you did not receive cretostimogene. People in the study will continue to be monitored by cystoscopy and pathology to see how long it takes for thecancer to return.Who May Be Eligible to Take Part In This Study:People with:• Bladder Cancer that has not invaded the muscle (Non-Muscle Invasive Bladder Cancer) • Intermediate-Risk Disease • Over 18AllTreatment:18All patients will receive surgical treatment on study as part of Standard-of-Care. 50% of patients will receive cretostimogene in addition to surgical treatment. For patients who do not receive cretostimogene, you will be offered cretostimogene if your bladder cancer recurs. The treatment will be instilled into the bladder through a thin tube called a catheter. This will be done 14 times over an 12-month period.Main Meausure:Patients who have recurrence of bladder cancer after receiving surgery plus cretostimogene compared to patients who receive surgery alone.

if you decide to take part in this study and meet all of the requirements, all patients will receive surgical treatment on study as part of Standard-of-Care. 50% of patients will receive cretostimogene in addition to surgical treatment. For patients who do not receive cretostimogene, you will be offered cretostimogene if your bladder cancer recurs. You will receive 6 treatments, once per week for 6 weeks in a row. The treatment will be instilled into the bladder through a thin tube called a catheter. This will be done 14 times over an 12-month period. There will be up to 16 visits with blood draw and/or urine colelction. As a part of screening, efficacy and follow up for this study, you might have to have cystoscopy ( up to 6), urine cytology (up to 6), TUBRT or vladder mapping or CT urogram over a 3 year month period.

To determine if chemotherapy added to ovarian suppression and endocrine therapy is better than endocrine therapy and ovarian supression alone.

Subjects will be required to keep all study appointments, take the medications as required, have an annual mammogram, inform the study of any over the counter medications they may be taking.

The goal of the proposed project is to identify biosignatures that predict resilience or vulnerability to the transition from acute to chronic pain in a cohort of patients recovering from an acute musculoskeletal trauma.

There is one in person visit that will include a 30-min MRI scan, sensory testing, and blood draw. Two follow-up surveys will be sent to the participants at 3- and 6-months following their injury.

$200

To evaluate the effect of cabozantinib in combination with avelumab on OS compared to avelumab alone in patients with mUC who did not progress during first-line platinum-based chemotherapy therapy, i.e. patients who had CR, PR or SD after completion of first line platinum-based chemotherapy.

Patients will be expected to come to all clinic appointments, have labs drawn on the first day of every cycle, take medications as prescribed, return all empty pill bottles and diary, and call the clinic with questions.

In this project, we aim to extend the capabilities of smart-speakers (such as Amazon Alexa, Google Home, Siri, etc.) to support more engaging interactions with their users. Specifically, we would like to make the future of smart-speakers more conversational. One of the key aspects in developing a conversation is to be an active listener; showing interest in the speaker and allowing them to extend their turn in talk. In this study we investigate how smart-speakers can become better listeners by incorporating some of the human-human conversational features of active listening. Our question is, how can smart-speakers extend the users' turn in talk by being better listeners?

This study will examine the effects of different brain games on cognitive and everyday activities in middle-aged and older adults. Participants will play either 20 or 40 hours of ENACT brain games on a study provided laptop. They will also complete daily surveys on a study-provided mobile phone for the duration of the study. These surveys will take approximately 5-6 minutes to complete per day. The study will last either 6 or 9 months depending on the brain game training time. The study will be done remotely from the comfort of home using study-provided mobile devices. Participants are compensated for their time.

Participants will play either 20 or 40 hours of ENACT brain games on a study provided laptop. They will also complete daily surveys on a study-provided mobile phone for the duration of the study. These surveys will take approximately 5-6 minutes to complete per day. The study will last either 6 or 9 months depending on the brain game training time. The study will be done remotely from the comfort of home using study-provided mobile devices.

$230